INTELGENX TECHNOLOGIES CORP.
IGXT evidence brief
What we can confirm
- BioSniper Score:
- 8.6 / 10
- Lead Asset:
- cannabis infused versafilm (Approved)
What it means
What to watch
Prepared research question
What matters most for IGXT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
cannabis infused versafilm (Approved)
Next Catalyst
—
Tracking 4 pipeline candidates for INTELGENX TECHNOLOGIES CORP..
Run INTELGENX TECHNOLOGIES CORP. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INTELGENX TECHNOLOGIES CORP. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is INTELGENX TECHNOLOGIES CORP.'s lead drug candidate?
INTELGENX TECHNOLOGIES CORP.'s most advanced tracked candidate is cannabis infused versafilm (Approved) for adult-used medical cannabis.
Who is the CEO of INTELGENX TECHNOLOGIES CORP.?
Dwight Gorham Dwight is the chief executive officer of INTELGENX TECHNOLOGIES CORP. (IGXT).
What therapeutic areas does INTELGENX TECHNOLOGIES CORP. focus on?
INTELGENX TECHNOLOGIES CORP. develops therapies across Neurology, Pain, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.